402 related articles for article (PubMed ID: 26965104)
1. Sinomenine down-regulates TLR4/TRAF6 expression and attenuates lipopolysaccharide-induced osteoclastogenesis and osteolysis.
He L; Duan H; Li X; Wang S; Zhang Y; Lei L; Xu J; Liu S; Li X
Eur J Pharmacol; 2016 May; 779():66-79. PubMed ID: 26965104
[TBL] [Abstract][Full Text] [Related]
2. Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca
Zeng XZ; Zhang YY; Yang Q; Wang S; Zou BH; Tan YH; Zou M; Liu SW; Li XJ
Acta Pharmacol Sin; 2020 Feb; 41(2):229-236. PubMed ID: 31431733
[TBL] [Abstract][Full Text] [Related]
3. Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling.
Zhang Y; Zou B; Tan Y; Su J; Wang Y; Xu J; Tao L; Zhou H; Liu L; Li X
Pharmacol Res; 2019 Apr; 142():140-150. PubMed ID: 30797069
[TBL] [Abstract][Full Text] [Related]
4. Blockade of NF-κB and MAPK pathways by ulinastatin attenuates wear particle-stimulated osteoclast differentiation in vitro and in vivo.
Ru JY; Xu HD; Shi D; Pan JB; Pan XJ; Wang YF
Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27638499
[TBL] [Abstract][Full Text] [Related]
5. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
6. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
7. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades.
Song F; Wei C; Zhou L; Qin A; Yang M; Tickner J; Huang Y; Zhao J; Xu J
J Cell Physiol; 2018 Feb; 233(2):1723-1735. PubMed ID: 28681916
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
9. Sinomenine suppresses osteoclast formation and Mycobacterium tuberculosis H37Ra-induced bone loss by modulating RANKL signaling pathways.
Li X; He L; Hu Y; Duan H; Li X; Tan S; Zou M; Gu C; Zeng X; Yu L; Xu J; Liu S
PLoS One; 2013; 8(9):e74274. PubMed ID: 24066131
[TBL] [Abstract][Full Text] [Related]
10. Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling.
Thummuri D; Jeengar MK; Shrivastava S; Nemani H; Ramavat RN; Chaudhari P; Naidu VG
Pharmacol Res; 2015 Sep; 99():63-73. PubMed ID: 26022736
[TBL] [Abstract][Full Text] [Related]
11. Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.
Meng J; Zhou C; Zhang W; Wang W; He B; Hu B; Jiang G; Wang Y; Hong J; Li S; He J; Yan S; Yan W
J Cell Mol Med; 2019 Oct; 23(10):6730-6743. PubMed ID: 31328430
[TBL] [Abstract][Full Text] [Related]
12. The protective effect of berberine hydrochloride on LPS‑induced osteoclastogenesis through inhibiting TRAF6‑Ca2+‑calcineurin‑NFATcl signaling pathway.
Ye F; Zhou Q; Tian L; Lei F; Feng D
Mol Med Rep; 2017 Nov; 16(5):6228-6233. PubMed ID: 28849049
[TBL] [Abstract][Full Text] [Related]
13. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.
Thummuri D; Naidu VGM; Chaudhari P
J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855
[TBL] [Abstract][Full Text] [Related]
14. Geraniin suppresses RANKL-induced osteoclastogenesis in vitro and ameliorates wear particle-induced osteolysis in mouse model.
Xiao F; Zhai Z; Jiang C; Liu X; Li H; Qu X; Ouyang Z; Fan Q; Tang T; Qin A; Gu D
Exp Cell Res; 2015 Jan; 330(1):91-101. PubMed ID: 25016282
[TBL] [Abstract][Full Text] [Related]
15. Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathways.
Wu Z; Wu H; Li C; Fu F; Ding J; Shao S; Li K; Yu X; Su Y; Liang J; Lin X; Yuan G; Zhou J; Song F; Zhao J; Xu J; Liu Q; Xu F
J Cell Physiol; 2019 Aug; 234(10):17812-17823. PubMed ID: 30815894
[TBL] [Abstract][Full Text] [Related]
16. Vaccarin prevents titanium particle-induced osteolysis and inhibits RANKL-induced osteoclastogenesis by blocking NF-κB and MAPK signaling pathways.
Liu Y; Song FM; Ma ST; Moro A; Feng WY; Liao SJ; Lin XX; Zhao JM; Wang ZY; Xu J; Zhan XL; Liu Q
J Cell Physiol; 2019 Aug; 234(8):13832-13842. PubMed ID: 30637734
[TBL] [Abstract][Full Text] [Related]
17. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
[TBL] [Abstract][Full Text] [Related]
18. TRAF6 is functional in inhibition of TLR4-mediated NF-κB activation by resveratrol.
Jakus PB; Kalman N; Antus C; Radnai B; Tucsek Z; Gallyas F; Sumegi B; Veres B
J Nutr Biochem; 2013 May; 24(5):819-23. PubMed ID: 22925919
[TBL] [Abstract][Full Text] [Related]
19. Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells.
Guo C; Hou GQ; Li XD; Xia X; Liu DX; Huang DY; Du SX
Cell Physiol Biochem; 2012; 30(1):123-36. PubMed ID: 22759961
[TBL] [Abstract][Full Text] [Related]
20. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR
Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
